






  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="robots" content="noindex,nofollow"/>
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn&apos;s Disease - Tabular View - ClinicalTrials.gov</title>
    <link href="/ct2/show/record/NCT00409682" rel="canonical"/>
  
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish-vertical.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/base.css?v=b4" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/print.css" media="print" />
  <link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct.css" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct-oldIE.css" type="text/css" />
  <![endif]-->
  	

     <!--[if lte IE 7]>
           <link href="/ct2/html/ct3/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
    <![endif]-->

<link href="/ct2/html/ct3/css/trial-record.css?v=b4" rel="stylesheet" type="text/css" />
<link href="/ct2/html/ct3/css/ct2Header.css" rel="stylesheet" type="text/css" />


	<script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.min.js?v=1.12.4"></script><noscript></noscript>
	    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/superclick.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.cookie.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/images/frame/ct.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/js/ctmenu.js?v=b4"></script><noscript></noscript>

    <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script><noscript></noscript>
<script type="text/javascript">
    $(window).load(function(){
        loadCTCommon();
        });
</script>
 


  <script type="text/javascript">
    ncbi_pingWithImage=true;
    __ncbi_stat_url="//www.ncbi.nlm.nih.gov/stat";        
  </script>
  
  <meta name="ncbi_sid" content="8615078f985f84e6_a636bSID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_record"/>
  <meta name="ncbi_pcid" content="NCT00409682"/>
  <meta name="ncbi_ctreqid" content="RRf02r8T"/>
  <meta name="ncbi_ctsessid" content="SRf02JsB"/>
  <meta name="ncbi_ctipid" content="IzOkI5NS"/>
  <meta name="ncbi_cthost" content="wp1"/>
</head>

<body class="js one-column"> 
<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>

<script type="text/javascript">
	var RetractableBannerStateProperty = 'CT_NewsBannerState';
	
	ToggleBanner = function()
    {
        var theAccordion = $('#retractableBanner'); 
       	if (theAccordion.css("display") == "none") {
        		$('#showMore').css('visibility', 'hidden');
        	} else {
         		$('#showMore').css('visibility', 'visible');
        	}
        theAccordion.slideToggle({
            duration: 'fast',
            start: function(){
				            	if (typeof FuncReAlign !== 'undefined') {
            		$( "table.fixedHeader-floating" ).hide();
            	}
			},
            done: function(){
            	if (theAccordion.css("display") == "none") {
            		rememberRetractableBannerState('hide');
            	} else {
            		rememberRetractableBannerState('show');
            	}
            	if (typeof FuncReAlign !== 'undefined') {
                	FuncReAlign();  
            		$( "table.fixedHeader-floating" ).show();
            	}
            }
		});
    };
	    
	var rememberRetractableBannerState = function(newState) {
		try {
			sessionStorage.setItem(RetractableBannerStateProperty, newState);
		} catch (e) {}
	};

	$(window).ready(function(){
		try {
			var retractableBannerState = sessionStorage.getItem(RetractableBannerStateProperty);
					    if (retractableBannerState === null  || retractableBannerState === 'show') {
				ToggleBanner();
			}
		} catch (e) {};
	});
</script><noscript></noscript>
<div class="w3-container w3-center" style="padding:1.5ex 0.125in 0;background:#205493;color:white">
	<div style="font-weight:bold;">This site became the new ClinicalTrials.gov on June 19th. <a href="https://www.nlm.nih.gov/pubs/techbull/mj17/mj17_clinicaltrials_improve_usability.html" style="margin-left:1em;color:white;border-bottom-color:white;">Learn more.</a>
		<div id="showMore" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show more <img src="/ct2/html/ct3/images/show-more.png" style="width:17px;"></div>
	</div>
	<div id="retractableBanner" style="margin-top:1ex;display:none;">We will be updating this site in phases. This allows us to move faster and to deliver better services.
		<div id="showLess" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show less <img src="/ct2/html/ct3/images/show-less.png" style="width:17px;"></div>
	</div>
</div>
<div id="wrapper" style="padding-top:0;">  <div id="longAlert" class="w3-hide-small" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study.  <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>
<div id="shortAlert" class="w3-hide-medium w3-hide-large" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Talk with a trusted healthcare professional before volunteering for a study. <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>

  
	<div id="header" style="float:left;"> <a href="/ct2/home" style="border-style:none;box-shadow:none;"><img src='/ct2/html/ct3/images/ct.gov-logo.png' alt='ClinicalTrials.gov' style='max-width:100%;' /></a><br />
    	<div id="tagline">A service of the U.S. National Institutes of Health</div>
  	</div>
					<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/ct3/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
					</ul>
				</div>
    		</div>
  		</div>		

	  	<div id="savedStudies" style="float:right;padding:4px 8px;"> 		  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
		  	<button class="savedStudiesEnabled" id="open-cart-link" type="button" 
		  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
		  		title="Show previously saved studies.">Saved Studies</button>
		  	</div>
			<button class="savedStudiesDisabled" id="cart-disabled" type="button" disabled
				title="There are no saved studies to show. You can save studies to visit later from the search results page">Saved Studies (0)</button>
		</div>

		<div style="clear:right;text-align:right;padding-top:1ex;padding-right:8px;font-size:small;">
			<a href="https://survey.foreseeresults.com/survey/display?cid=WyHFr2m0PoaGCBUsi00QIQ==&sid=link-ct" target="_blank">Give us feedback</a></div>
		<script type="text/javascript" src="/ct2/html/ct3/js/cart.js?v=b4"></script><noscript></noscript>
  	
<div id="global-nav" class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
			<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
	</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div> 

<div id="utilities">
     
</div>
<div id="breadcrumb">
	<ul class="horz-list">
		<li><a href="/ct2/home">Home</a></li>
				<li class="last">Study Record Detail</li>
	</ul>
</div>


<div id="main-content">


        	<h1 class="solo_record">Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease</h1>
	<div id="trial-info-1" class="floater-50">

     


      
        <div  class="not-recruiting-status" >
      This study has been completed.
          </div>
        
        
      
        




                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> Abbott </div>



                              <div class="info-title">Information provided by:</div>
                <div class="info-text">Abbott</div>
              

            </div>
               <div id="trial-info-2" class="floater-50">
                <div class="info-title">ClinicalTrials.gov Identifier:</div>
                <div class="identifier">NCT00409682</div>
                <div class="info-date">First received: December 8, 2006</div>
                <div class="info-date">Last updated:  July 11, 2011</div>
                <div class="info-date">Last verified:  July 2011 </div>
                <div class="info-date"> <a href="/ct2/archive/NCT00409682"
          title="Historical versions of study NCT00409682 on ClinicalTrials.gov Archive Site - opens in new window"
          onclick="openNewWindow('/ct2/archive/NCT00409682'); return false;">History of Changes</a> </div>
            </div>



<div id="tabs">
        <ul id="tab-links">
			<li id="full-text" ><a href="/ct2/show/study/NCT00409682"  >Full Text View</a></li>
			<li id="tabular"     class="current"> Tabular View       </li>
			<li id="results"   ><a href="/ct2/show/results/NCT00409682">Study Results</a></li>
			<li id="disclaimer"><a href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
        </ul>
</div>  <div style="background-color:#f6f6f6;margin-top:3.5ex;padding-bottom:3.5ex;"> </div>




<!-- field list -->
<div class="indent1">
 
  <table class="w3-table data_table tableStyle">
    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Tracking Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">First Received Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">December 8, 2006</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Last Updated Date </th>
            <td class="body3 rowBody">July 11, 2011</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Start Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">April 2007</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">May 2010 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;July 11, 2011)</span></th>
            <td class="body3 rowBody">Percent of Participants With Clinical Remission as Defined by Pediatric Crohn&apos;s Disease Activity Index (PCDAI) Score &#8804; 10 at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Pediatric Crohn&apos;s Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn&apos;s Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The primary endpoint was clinical remission as defined by PCDAI score &#8804; 10. The comparison was between High-Dose adalimumab versus Low-Dose adalimumab in the intent-to-treat population.</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 8, 2006)</span></th>
            <td class="body3 rowBody">Rate of clinical remission as defined by PCDAI score</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Change History </th>
            <td class="body3 rowBody"><a href="/ct2/archive/NCT00409682" onclick="openNewWindow('/ct2/archive/NCT00409682'); return false;">Complete list of historical versions of study NCT00409682 on ClinicalTrials.gov Archive Site</a></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;July 11, 2011)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Percent of Participants With Clinical Remission as Defined by Pediatric Crohn&apos;s Disease Activity Index (PCDAI) Score &#8804; 10 at Week 52 [&nbsp;Time&nbsp;Frame:&nbsp;Week 52&nbsp;]<div class="indent2" style="margin-top:1ex;"><p style="margin-top:0ex; margin-bottom:1ex;">Pediatric Crohn&apos;s Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn&apos;s Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100 with higher scores indicating more active disease. Clinical remission was defined as PCDAI score of &#8804; 10.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">The comparison was between High-Dose adalimumab versus Low-Dose adalimumab in the intent-to treat population.</p></div></li>
<li style="margin:1ex 0.5ex">Percent of Participants With Clinical Response as Defined by Pediatric Crohn&apos;s Disease Activity Index (PCDAI) Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Pediatric Crohn&apos;s Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn&apos;s Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical response was defined as a decrease from Baseline in the PCDAI score of at least 15 points. The comparison was High-Dose adalimumab versus Low-Dose in the ITT population.</div></li>
<li style="margin:1ex 0.5ex">Percent of Participants With Clinical Response as Defined by Pediatric Crohn&apos;s Disease Activity Index (PCDAI) Score at Week 52 [&nbsp;Time&nbsp;Frame:&nbsp;Week 52&nbsp;]<div class="indent2" style="margin-top:1ex;">Pediatric Crohn&apos;s Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn&apos;s Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical response was defined as a decrease from Baseline in the PCDAI score of at least 15 points. The comparison was High-Dose adalimumab versus Low-Dose in the ITT population.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline IMPACT III Scores at Week 26 (Observed Case) [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The IMPACT III questionnaire is a 35-item assessment of health-related quality of life in patients with inflammatory bowel disease (Crohn&apos;s disease [CD] or ulcerative colitis). In this study, subjects greater than or equal 10 years old who had CD at baseline completed an IMPACT III questionnaire at Baseline, Week 26, and Week 52. Subjects marked an option from 1 to 5 for each item left to right with numbers 5 (good &apos;quality of life&apos; condition) through 1 (bad &apos;quality of life&apos; condition). The total scores, range from 35 to 175 with higher scores representing a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline IMPACT III Scores at Week 52 (Observed Case) [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and Week 52&nbsp;]<div class="indent2" style="margin-top:1ex;">The IMPACT III questionnaire is a 35-item assessment of health-related quality of life in patients with inflammatory bowel disease (Crohn&apos;s disease [CD] or ulcerative colitis). In this study, subjects greater than or equal 10 years old who had CD at baseline completed an IMPACT III questionnaire at Baseline, Week 26, and Week 52. Subjects marked an option from 1 to 5 for each item left to right with numbers 5 (good &apos;quality of life&apos; condition) through 1 (bad &apos;quality of life&apos; condition). The total scores, range from 35 to 175 with higher scores representing a better quality of life.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 8, 2006)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Patient Reported Outcomes</li>
<li style="margin:1ex 0.5ex">Clinical Response Indicators</li>
<li style="margin:1ex 0.5ex">Safety Parameters</li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Descriptive Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Official Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">A Multi-Center, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Summary </th>
            <td class="body3 rowBody">The purpose of this study is to determine Efficacy, Pharmacokinetics, and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Detailed Description </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">M06-806 (NCT # NCT00409682) was a Phase 3, multi-center, randomized, double-blind (DB), efficacy, safety, and pharmacokinetic (PK) study designed to evaluate the efficacy of 2 dose regimens for the induction and maintenance of clinical remission in pediatric subjects between the ages of 6 and 17 (inclusive) with moderate to severe Crohn's disease (CD) (defined by Pediatric Crohn's Disease Activity Index [PCDAI &gt; 30]). Subjects must have either failed conventional therapy for CD or have previously received infliximab and lost response/had intolerance to infliximab.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Approximately 186 pediatric subjects between the ages of 6 and 17 were planned to be entered into the study at approximately 55 sites in the US, Canada, and Europe. At least 80 subjects were to be &#8805; 13 years old at Baseline and one-third to one-half of the study population were to be subjects who had previously lost response or were intolerant to infliximab.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The duration of the study was to be up to 65 weeks, which included a 1- to 3-week Screening period, an Induction period, a Maintenance period, and a 70-day follow-up phone call for all subjects that either terminated early from the study or did not rollover into the extension study ([NCT # 00686374], to evaluate the long-term maintenance of clinical response, safety, and tolerability of repeated administration of adalimumab).</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">All subjects received an induction regimen administered at Baseline (Week 0) and Week 2. The open-label (OL) induction dose was based on the subject's Baseline body weight. Subjects weighing &#8805; 40 kg were to receive 160 mg at Week 0 and 80 mg adalimumab at Week 2. Subjects weighing &lt; 40 kg were to receive 80 mg at Week 0 and 40 mg adalimumab at Week 2.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">At Week 4, subjects were to be randomized 1:1 to 1 of 2 DB maintenance treatment groups (Low-Dose or High-Dose), stratified by Week 4 clinical responder status (clinical response was defined as decrease in PCDAI of &#8805; 15 points from the Baseline score), body weight at Week 4 and prior exposure to infliximab. Subjects randomized to the High-Dose treatment group were to receive either 40 mg adalimumab subcutaneous (SC) every other week (eow) (if Week 4 body weight &#8805; 40 kg) or 20 mg adalimumab SC eow (if Week 4 body weight &lt; 40 kg). Subjects randomized to the Low-Dose treatment group were to receive either 20 mg adalimumab SC eow (if Week 4 body weight &#8805; 40 kg) or 10 mg adalimumab SC eow (if Week 4 body weight &lt; 40 kg).</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Subject's body weight taken at Week 26 was to be used to readjust the maintenance dosing regimen for a subject whose body weight had increased from &lt; 40 kg to &#8805; 40 kg during the study.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Subjects were expected to remain on blinded eow therapy throughout the 48-week study DB Maintenance period. However, starting at the Week 12 study visit, subjects who experienced a disease flare (increase in the PCDAI &#8805; 15 points when compared to Week 4 and an absolute PCDAI above 30) or were non-responders (not achieving a decrease in the PCDAI score of at least 15 points when compared to the Baseline score for 2 consecutive visits at least 2 weeks apart) could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. During blinded ew treatment, if a subject continued to experience a flare or met the definition of non-response following an 8 week course of DB ew therapy, they were to be switched to OL ew therapy. The dosage of the OL ew therapy was 20 mg for subjects &lt; 40 kg and 40 mg for subjects &#8805; 40 kg.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">This study used the PCDAI to determine efficacy of the study drug. The primary efficacy endpoint is the proportion of subjects who are in clinical remission at Week 26, as measured by the PCDAI in the intent-to-treat population. Clinical remission is defined as a PCDAI score of &#8804; 10.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The clinical response indicators include clinical remission as defined by PCDAI score at Week 52 and clinical response as defined by PCDAI score at Week 26 and at Week 52.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The patient reported outcome is the change from Baseline in total IMPACT III scores at Week 26 and Week 52.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The safety parameters (adverse events, laboratory data, and vital signs) were assessed at all visits throughout the study.</p></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Type&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Interventional</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Phase </th>
            <td class="body3 rowBody">Phase 3</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Design&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Allocation: Randomized<br/>Intervention Model: Parallel Assignment<br/>Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)<br/>Primary Purpose: Treatment</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Condition&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Intervention&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Biological: Adalimumab
<div class="indent2" style="margin-top:0.5ex">All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.</div>
<div class="indent2" style="margin-top:0.5ex">Other Name: ABT-D2E7, adalimumab, Humira</div></li>
<li style="margin:1ex 0.5ex">Biological: Adalimumab
<div class="indent2" style="margin-top:0.5ex">Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.</div>
<div class="indent2" style="margin-top:0.5ex">Other Name: ABT-D2E7, adalimumab, Humira</div></li>
<li style="margin:1ex 0.5ex">Biological: Adalimumab
<div class="indent2" style="margin-top:0.5ex">Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.</div>
<div class="indent2" style="margin-top:0.5ex">Other Name: ABT-D2E7, adalimumab, Humira</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Arms </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Active Comparator: Open-label adalimumab (Week 0 to Week 4)
<div class="indent2" style="margin-top:0.5ex">All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Adalimumab</div></li>
<li style="margin:1ex 0.5ex">Active Comparator: Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)
<div class="indent2" style="margin-top:0.5ex">Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Adalimumab</div></li>
<li style="margin:1ex 0.5ex">Active Comparator: High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)
<div class="indent2" style="margin-top:0.5ex">Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Adalimumab</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Publications * </th>
            <td class="body3 rowBody"><a class="study-link" href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0nLg0nER0jA6h9Ei4L3BUgWwNG0it." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0nLg0nER0jA6h9Ei4L3BUgWwNG0it.'); return false">Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, Dubinsky M, Kierkus J, Rosh J, Wang Y, Huang B, Bittle B, Marshall M, Lazar A. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012 Aug;143(2):365-74.e2. doi: 10.1053/j.gastro.2012.04.046. Epub 2012 May 2.</a></td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        * &nbsp; Includes publications given by the data provider as well as publications
        identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
      </td>
    </tr>

    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Recruitment Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Recruitment Status&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Completed</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Enrollment&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">192</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Completion Date </th>
            <td class="body3 rowBody">May 2010</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">May 2010 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Eligibility Criteria&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Subjects between the ages of 6 and 17, inclusive, prior to baseline dosing.</li>
    <li style="margin-top:0.7ex;">Subjects with a diagnosis of Crohn's disease for greater than 12 weeks prior to screening, confirmed by endoscopy or radiologic evaluation.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">PCDAI &gt; 30 despite concurrent treatment with an oral corticosteroid, and/or azathioprine (AZA) or 6-mercaptopurine (6-MP) or methotrexate (MTX) as defined below:</p>
      <ul style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Oral corticosteroid - Prednisone of &#8805; 10 mg/day or equivalent, but not exceeding 40 mg, with a stable dose for at least two weeks prior to Baseline.</li>
        <li style="margin-top:0.7ex;">Azathioprine or 6-MP - AZA dose of &#8805; 1.5 mg/kg/day or 6-MP dose of &#8805; 1 mg/kg/day rounded to the nearest available tablet formulation, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.</li>
        <li style="margin-top:0.7ex;">MTX dose of &#8805; 5 mg once weekly, either subcutaneously (SC), intramuscularly (IM), or orally for subjects whose body weight is &#8805; 20 kg, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.</li>
        <li style="margin-top:0.7ex;">MTX dose of 0.2 mg/kg, up to 5 mg, once weekly, either SC, IM, or orally for subjects whose body weight is &lt; 20 kg, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.</li>
        <li style="margin-top:0.7ex;">
          <p style="margin-top:0ex; margin-bottom:1ex;">Concurrent therapy will not be required for subjects who within the past 2 years in the opinion of the Investigator have not responded to or could not tolerate systemic corticosteroids, AZA, 6-MP, or MTX as defined below:</p>
          <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">
              <p style="margin-top:0ex; margin-bottom:1ex;">Corticosteroids:</p>
              <ul style="margin-top:1ex; margin-bottom:1ex;">
                <li style="margin-top:0.7ex;">Failed to successfully respond to corticosteroids, or</li>
                <li style="margin-top:0.7ex;">Medical complications and/or adverse events (AEs) from corticosteroids that in the judgment of their physician, precludes their use (e.g. psychosis, uncontrolled diabetes, osteoporosis, or osteonecrosis).</li>
              </ul>
            </li>
            <li style="margin-top:0.7ex;">
              <p style="margin-top:0ex; margin-bottom:1ex;">Azathioprine, 6-MP or MTX: -</p>
              <ul style="margin-top:1ex; margin-bottom:1ex;">
                <li style="margin-top:0.7ex;">Failed to successfully respond to these drugs or</li>
                <li style="margin-top:0.7ex;">Medical complications and/or AEs that in the judgment of their physician, precludes their use (e.g. allergic reaction, pancreatitis, elevated liver enzymes, hepatitis or leukopenia).</li>
              </ul>
            </li>
          </ul>
        </li>
      </ul>
    </li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">If female, subjects who were sexually active and were of child-bearing potential practicing an approved method of birth control throughout the study and for 150 days after study completion. Examples of approved methods of birth control included the following:</p>
      <ul style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Condoms, sponge,foam,jellies,diaphragm, or intrauterine device (IUD)</li>
        <li style="margin-top:0.7ex;">Oral,parenteral, or intravaginal contraceptives for 12 weeks prior to adalimumab administration</li>
        <li style="margin-top:0.7ex;">A vasectomized partner.</li>
      </ul>
    </li>
    <li style="margin-top:0.7ex;">Parent or legal guardian,as required,had voluntarily signed and dated an informed consent form (IFC), approved by an Institutional Review Board (IRB)/ Independent Ethics Committee (IEC).</li>
    <li style="margin-top:0.7ex;">Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by Screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.</li>
    <li style="margin-top:0.7ex;">Parent or legal guardian was willing to actively supervise storage and administration of study drug and to ensure that the time of each dose was accurately recorded in the subject's diary.</li>
    <li style="margin-top:0.7ex;">Subjects who had previously received infliximab, providing the subject had an initial response and then discontinued use due to a loss of response, or discontinued use due to intolerance.</li>
  </ol>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma-in-situ of the cervix.</li>
    <li style="margin-top:0.7ex;">History of listeria, histoplasmosis, chronic or active hepatitis B infection, human immunodeficiency virus (HIV), an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease, or active tuberculosis (TB) (receiving treatment or not receiving treatment), severe infections such as sepsis and opportunistic infections.</li>
    <li style="margin-top:0.7ex;">Subject with infectious colitis, ulcerative colitis or indeterminate colitis as determined by the investigator and Abbott Medical Monitor.</li>
    <li style="margin-top:0.7ex;">Subject with symptomatic known obstructive strictures.</li>
    <li style="margin-top:0.7ex;">Subject who had surgical bowel resections within the past 24 weeks of the Baseline visit or planned any resection at any time point while enrolled in the study.</li>
    <li style="margin-top:0.7ex;">Subject with an ostomy or ileo-anal pouch. (Subjects with a previous ileo-rectal anastomosis were not excluded).</li>
    <li style="margin-top:0.7ex;">Subject who had short bowel syndrome as determined by the investigator.</li>
    <li style="margin-top:0.7ex;">Subject who was currently receiving total parenteral nutrition (TPN).</li>
    <li style="margin-top:0.7ex;">Females who were pregnant or were currently breast-feeding.</li>
    <li style="margin-top:0.7ex;">Subject who had received any investigational chemical agent in the past 30 days or 5 half-lives prior to Baseline (whichever was longer).</li>
    <li style="margin-top:0.7ex;">Subject who had received any investigational biological agent in the past 16 weeks or 5 half-lives prior to Baseline (whichever was longer).</li>
    <li style="margin-top:0.7ex;">Subject who has had systemic antibiotic, antiviral or antifungal treatment(s) within 3 weeks prior to Baseline for any non-Crohn's related infections.</li>
    <li style="margin-top:0.7ex;">Subject with a history of clinically significant drug or alcohol abuse in the last year.</li>
    <li style="margin-top:0.7ex;">Subjects with a poorly controlled medical condition such as: uncontrolled diabetes, recurrent infections, unstable ischemic heart disease, moderate to severe heart failure, recent cerebrovascular accidents and any other condition which, in the opinion of the investigator or the Sponsor, would put the subject at risk by participation in the protocol.</li>
    <li style="margin-top:0.7ex;">Subjects with positive C. difficile stool assay.</li>
    <li style="margin-top:0.7ex;">Subject who previously used infliximab within eight weeks of Baseline.</li>
    <li style="margin-top:0.7ex;">Subject who previously used infliximab and had not clinically responded at any time (&quot;primary non-responder&quot;) unless subject experienced a treatment limiting reaction to infliximab.</li>
    <li style="margin-top:0.7ex;">Previous treatment with any other anti-TNF agent except infliximab.</li>
    <li style="margin-top:0.7ex;">Received previous treatment with adalimumab or previous participation in an adalimumab clinical study.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Screening laboratory and other analyses showing any of the following abnormal results:</p>
      <ul style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Electrocardiogram (ECG) &#8722; with clinically significant abnormalities;</li>
        <li style="margin-top:0.7ex;">Aspartate transaminase (AST) or alanine transaminase (ALT) &gt;1.75 x the upper limit of the reference range;</li>
        <li style="margin-top:0.7ex;">Total bilirubin &#8805; 3 mg/dL;</li>
        <li style="margin-top:0.7ex;">Serum creatinine &gt; 1.6 mg/dL;</li>
      </ul>
    </li>
    <li style="margin-top:0.7ex;">Subjects on AZA, 6-MP, or MTX who had not been on these medications for at least 8 weeks prior to Baseline and on stable doses of these medications for at least 4 weeks prior to Baseline. Subjects who had been on AZA, 6-MP, or MTX who had discontinued these medications within 8 weeks of Baseline.</li>
    <li style="margin-top:0.7ex;">Subjects on aminosalicylates, or Crohn's-related antibiotics (fluoroquinolones such as ciprofloxacin or nitroimidazole derivatives such as metronidazole) that had not been on stable doses of these medications for at least 4 weeks prior to Baseline. In addition, subjects on aminosalicylates or Crohn's-related antibiotic treatments who had discontinued these medications within four weeks of Baseline.</li>
    <li style="margin-top:0.7ex;">Subjects on prednisone &gt; 40 mg/day (or equivalent) or subjects on &lt; 10 mg/day prednisone and subjects who were not on a stable dose for at least 2 weeks prior to Baseline. In addition, subjects who discontinued prednisone (or equivalent) within 2 weeks of Baseline.</li>
    <li style="margin-top:0.7ex;">Subjects on growth hormone that had not been on a stable dose for at least 12 weeks prior to Baseline. Subjects had to consent to remain on a stable dose through the duration of the study.</li>
    <li style="margin-top:0.7ex;">Subjects on budesonide &gt; 9 mg/day and subjects who were not on stable doses for at least 2 weeks prior to Baseline. In addition, subjects who discontinued budesonide within 2 weeks of Baseline.</li>
    <li style="margin-top:0.7ex;">Subjects who were currently taking both budesonide and prednisone (or equivalent).</li>
    <li style="margin-top:0.7ex;">Subjects who had undergone therapeutic enemas within two weeks prior to Baseline.</li>
    <li style="margin-top:0.7ex;">Subjects who had been on cyclosporine (intravenous [IV], oral), tacrolimus (any form), or mycophenolate mofetil within 28 days of Baseline.</li>
    <li style="margin-top:0.7ex;">Subjects who had been on Kineret&#174; (anakinra) must discontinue use 2 days prior to Baseline.</li>
    <li style="margin-top:0.7ex;">Subjects with any prior exposure to Tysabri (natalizumab).</li>
    <li style="margin-top:0.7ex;">Subjects with known hypersensitivity to the excipients of adalimumab as stated in the label.</li>
    <li style="margin-top:0.7ex;">Subjects with a previous history of dysplasia of the gastrointestinal tract.</li>
    <li style="margin-top:0.7ex;">Subjects who weighed &lt; 17 kg at Screening.</li>
    <li style="margin-top:0.7ex;">Subject not in compliance with prior and concomitant medications.</li>
  </ol></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Sex/Gender </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Sexes Eligible for Study:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">All</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Ages </th>
            <td class="body3 rowBody">6 Years to 17 Years &nbsp; (Child)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Accepts Healthy Volunteers </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Contacts&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><i style="color:#777777">Contact information is only displayed when the study is recruiting subjects</i></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Listed Location Countries&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Belgium, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; France, &nbsp; Netherlands, &nbsp; Poland, &nbsp; United Kingdom, &nbsp; United States</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Removed Location Countries </th>
            <td class="body3 rowBody">Italy</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Administrative Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">NCT Number&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">NCT00409682</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Other Study ID Numbers&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">M06-806<br> 2006-004814-41 ( EudraCT Number )</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Has Data Monitoring Committee </th>
            <td class="body3 rowBody">Yes</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">U.S. FDA-regulated Product </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">IPD Sharing Statement </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Responsible Party </th>
            <td class="body3 rowBody">Andreas Lazar, Abbott</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Sponsor&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Abbott</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Collaborators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Investigators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Study Director:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Roopal Thakkar</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Abbott</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">PRS Account </th>
            <td class="body3 rowBody">Abbott</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Verification Date </th>
            <td class="body3 rowBody">July 2011</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        <sup style="color:blue"> ICMJE </sup>&nbsp; &nbsp; Data element required by the
        <a href="http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">
        International Committee of Medical Journal Editors</a> and the
        <a href="http://www.who.int/ictrp/network/trds/en/index.html">World Health Organization ICTRP</a>
      </td>
    </tr>

  </table>
</div>


<div id="to-top"><a href="#wrapper">To Top</a></div>

	<div style="clear:both;"></div>
</div> 

      <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

<div id="footer-menu">
    <ul class="horz-list">
		<li><a href="/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a     href="/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a         href="/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a       href="/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a        href="https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00409682" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00409682'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li                  ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li                  ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li                  ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li                  ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li                  ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

    <script type="text/javascript" src="/ct2/html/ct3/js/instrumentNCBIBaseJS.min.js"></script><noscript></noscript>

</body>
</html>
